TPG portfolio company Par Pharma ups debt, draws downgrade
Standard & Poor’s has downgraded generic drug maker Par Pharmaceutical Cos’s credit rating as it takes on more debt to acquire JHP Pharmaceuticals as an add-on. The move could mark a fresh challenge for the company’s owner, TPG Capital, as it raises a bridge fund for its next flagship private equity pool.
3 February 2014•3 mins read
